agarwaleye Limited
Minimum investment
Bidding date
29 Jan - 31 Jan 2025
Price range
—
Minimum quantity
35
Minimum investment
₹13,370
Issue size
—
IPO doc (link)
RHP docsListing exchange
NSE/BSE
Dr Agarwal's Health Care Limited provides a comprehensive range of eye care services, including cataract, refractive, and other surgeries; consultations, diagnoses, and non-surgical treatments; and sell opticals, contact lenses, and accessories, and eye care related pharmaceutical products. Company had a market share of approx 25% of the total eye care service chain market in India during FY 2024, the chain comprises 209 Facilities and 737 doctors and they served 2.13 million patients and performed 220,523 surgeries in FY 2024.
The Indian eye care industry is projected to grow at a CAGR of 12% to 14% from FY 2024 to FY 2028. The size of the Indian eye care services industry was approximately Rs 378 billion in FY 2024, and is projected to grow to Rs 550 – 650 billion by FY 2028.
Largest eye care services provider: Dr Agarwal's Health Care India’s largest eye care service chain by revenue from operations for the FY 2024, with approx 1.7 times the revenue from operations of the second-largest eye care service chain in the country during such period.
Comprehensive eye care : Company is an end-to-end eye care services provider offering a comprehensive set of services, which allows them to cater to all ophthalmic needs of patients.
Scalable asset-light model: Company's network operates on a hub-and-spoke model which supports high patient volumes and yields economies of scale, allowing greater accessibility and choice to patients along with low upfront investment.
Distinguished leadeship: Company's founder late Dr. Jaiveer Agarwal, was awarded the prestigious Padma Bhushan in 2006 in recognition of his distinguished contribution to medicine. Chairperson, Dr. Amar Agarwal, has pioneered multiple surgical innovations in ophthalmology.
Dependence on medics: Company engages doctors through retainership arrangements and there is no assurance that doctors will not prematurely terminate their arrangements with them.
Highly regulated industry: Company operates in a regulated industry, any failure to comply with applicable safety, health, environmental, labor, and other regulations, or to obtain or renew approvals, may adversely affect business.
Regional concentration: A significant majority of Facilities are located in the states of Tamil Nadu (in particular, Chennai), Maharashtra and Karnataka in India and any adverse developments in relation to these Facilities could adversely affect business.